Direxion Daily CSI 300 China A Share Bull 2X Shares (ARCA: CHAU)

Ultime notizie per Direxion Daily CSI 300 China A Share Bull 2X Shares (ARCA:CHAU)

Direxion Daily CSI 300 China A Share Bull 2X Shares

Financial Services

Direxion

The fund invests at least 80% of its net assets (plus borrowing for investment purposes) in financial instruments, such as swap agreements, and securities of the index, ETFs that track the index and other financial instruments that provide daily leveraged exposure to the index or to ETFs that track the index. The index is a modified free-float market capitalization weighted index comprised of the largest and most liquid stocks in the Chinese A-share market. The fund is non-diversified.

Deutsche Bank Ag

Goldman Sachs Fin Gov 465 Institut

Dreyfus Government Cash Manage

Dreyfus Govt Cash Man Ins

Gs Financial Square Treasury Instruments Fund

Dreyfus Trsy Prime Cash Mgmt - In 0 -

JMP Securities analyst Jordan Bender reiterates Caesars Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) with a Market Outperform and maintains $45 price target.

News

Price Target

Reiteration

Analyst Ratings

JMP Securities Reiterates Market Outperform on Caesars Entertainment, Maintains $45 Price Target

UBS analyst Francois-Xavier Bouvignies maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Buy and lowers the price target from $265 to $250.

NXPI

UBS Maintains Buy on NXP Semiconductors, Lowers Price Target to $250

Rumors

Trading Ideas

NVDA

UPDATE: Nvidia CEO Jensen Huang In CNBC Interview Reportedly Says I'm Certain We Can Manufacture Chips On Shore With Resources Of Our Country

UBS analyst Joshua Chan maintains Kforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFRC#NYSE">KFRC</a>) with a Neutral and lowers the price target from $47 to $40.

KFRC

UBS Maintains Neutral on Kforce, Lowers Price Target to $40

A closely watched inflation gauge used by U.S. policymakers cooled in March, signaling easing price pressures ahead of the April 2 tariff announcement, as consumers and businesses assessed <a href="https://www.benzinga.com/news/econ-s">the potential economic impact.</a>
The Personal Consumption Expenditures (PCE) price index rose 2.3% year-over-year, slowing from February's upwardly revised 2.7% and just slightly above expectations of 2.2%. On a monthly basis, headline PCE was unchanged, a sharp deceleration from the 0.4% increase seen in February, and matching expectations.
Stripping out food and energy, core PCE, the Federal Reserve's preferred inflation measure, came in at 2.6% year-over-year, matching forecasts but down from February's revised 3%. 
On a monthly basis, core prices were flat, defying consensus for a 0.1% rise and cooling from the prior 0.4% surge.
Before the PCE report, the U.S. Bureau of Economic Analysis reported that first-quarter GDP contracted by 0.3% on an annualized basis, a sharp reversal from the 2.4% growth in the previous quarter and well below expectations for a 0.4% expansion.
Money markets are currently pricing in a 65% chance of a 25-basis-point interest rate cut by the Federal Reserve&#8217;s June meeting.
<h3 class="wp-block-heading">Automobile Spending Soars As Consumers Front-Run Tariffs</h3>
Personal income rose 0.5% month-over-month, slightly beating expectations of 0.4%, though slowing from February's revised 0.7% increase. 
Meanwhile, personal spending increased by 0.7% as consumers rushed to get ahead of the tariff impact. The outcome marks an increase from February's 0.5% and well above the 0.4% forecast.
Of the $134.5 billion monthly increase in spending, $56.6 billion was allocated to motor vehicles and parts, indicating precautionary buying behavior ahead of potential price increases. 
Spending on gasoline and other energy goods fell by $29.8 billion. 
<h3 class="wp-block-heading">Market Reactions: Stocks Slide As Traders Digest Mixed Macro Signals</h3>
The inflation cooldown failed to calm markets, as strong spending and tariff-related distortions sparked fears of policy uncertainty and stagflation.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major</td>
<td>Price</td>
<td>Day</td>
<td>Day (%)</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5448.76</td>
<td>-112 pts</td>
<td>-2.01%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,831</td>
<td>-696 pts</td>
<td>-1.72%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,061</td>
<td>-484 pts</td>
<td>-2.48%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,924.95</td>
<td>-54 pts</td>
<td>-2.75%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 10:10 a.m. ET</figcaption></figure>
S&amp;P 500 Top Gainers
<ul>
<li>Seagate Technology Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) up 7.7% to $87.85</li>
<li>Trane Technologies plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>) up 5.5% to $372.88</li>
<li>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) up 4.7% to $42.52</li>
<li>GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) up 4.0% to $70.83</li>
<li>PPG Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) up 3.7% to $107.67</li>
</ul>
S&amp;P 500 Top Losers
<ul>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) down 15.6% to $30.37</li>
<li>Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) down 10.5% to $15.55</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) down 9.4% to $124.28</li>
<li>Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) down 8.1% to $53.96</li>
<li>Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) down 7.5% to $78.45</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/45100047/recession-odds-spike-wall-street-tumbles-as-q1-gdp-surprisingly-contracts-be-patient-trump-responds">Recession Odds Spike, Wall Street Tumbles As Q1 GDP Surprisingly Contracts: &#8216;Be Patient,&#8217; Trump Responds</a></li>
</ul>
Photo: RozenskiP / Shutterstock.com

Equities

Government

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

ETFs

FSLR

GEHC

NCLH

SBUX

SMCI

Fed's Preferred Inflation Gauge Eases, Yet Tariff-Driven Auto Spending Clouds Outlook

WIIM

Camping World Holdings shares are trading lower after the company reported mixed Q1 financial results.

Baird analyst Jeffrey Meuler maintains Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) with a Neutral and raises the price target from $1775 to $1837.

FICO

Baird Maintains Neutral on Fair Isaac, Raises Price Target to $1837

Houlihan Lokey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLI#NYSE">HLI</a>) has outperformed the market over the past 5 years by 8.43% on an annualized basis producing an average annual return of 22.18%. Currently, Houlihan Lokey has a market capitalization of $11.38 billion. 
Buying $1000 In HLI: If an investor had bought $1000 of HLI stock 5 years ago, it would be worth $2,736.94 today based on a price of $162.22 for HLI at the time of writing.
<h3>Houlihan Lokey's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746023411_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Baird analyst Andrew Wittmann maintains Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) with a Neutral and lowers the price target from $277 to $273.

Baird Maintains Neutral on Ecolab, Lowers Price Target to $273

UBS analyst Caio Greiner maintains Gerdau (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GGB#NYSE">GGB</a>) with a Neutral and lowers the price target from $3.3 to $2.9.

UBS Maintains Neutral on Gerdau, Lowers Price Target to $2.9

Subsea 7 (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SUBCY#OTC">SUBCY</a>) reported quarterly earnings of $0.06 per share. This is a 33.33 percent decrease over earnings of $0.09 per share from the same period last year. The company reported $1.53 billion in sales this quarter. This is a 9.61 percent increase over sales of $1.40 billion the same period last year.

Earnings

SUBCY

Subsea 7 Q1 EPS $0.06 Down From $0.09 YoY, Sales $1.53B Up From $1.40B YoY

XPO shares are trading higher after the company reported better-than-expected Q1 EPS results.

Baird analyst Richard Eastman maintains Zebra Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) with a Outperform and raises the price target from $286 to $290.

ZBRA

Baird Maintains Outperform on Zebra Technologies, Raises Price Target to $290

UBS analyst Jon Windham maintains First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Buy and lowers the price target from $240 to $235.

UBS Maintains Buy on First Solar, Lowers Price Target to $235

Offerings

FCEL

FuelCell Energy Files For Mixed Shelf Of Up To $200M

Fuchs Petrolub (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUPBY#OTC">FUPBY</a>) reported quarterly earnings of $0.16 per share. This is unchanged from the same period last year. The company reported $971.68 million in sales this quarter. This is a 2.02 percent increase over sales of $952.47 million the same period last year.

FUPBY

Fuchs Petrolub Q1 EPADS $0.16, Sales $971.68M Up From $952.47M YoY

UBS analyst Tim Chiodo maintains Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) with a Buy and lowers the price target from $138 to $125.

FOUR

UBS Maintains Buy on Shift4 Payments, Lowers Price Target to $125

JMP Securities analyst Nicholas Jones reiterates CoStar Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) with a Market Outperform and maintains $85 price target.

CSGP

JMP Securities Reiterates Market Outperform on CoStar Group, Maintains $85 Price Target

Baird analyst Michael Halloran maintains Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Outperform and lowers the price target from $149 to $146.

Baird Maintains Outperform on Xylem, Lowers Price Target to $146

<a href="https://www.gov.uk/government/news/mhra-authorises-cancer-treatment-variation-with-an-administration-time-of-3-5-minutes#:~:text=The%20subcutaneous%20formulation%20of%20nivolumab,and%20head%20and%20neck%20cancers" title="https://www.gov.uk/government/news/mhra-authorises-cancer-treatment-variation-with-an-administration-time-of-3-5-minutes#:~:text=The%20subcutaneous%20formulation%20of%20nivolumab,and%20head%20and%20neck%20cancers">https://www.gov.uk/government/news/mhra-authorises-cancer-treatment-variation-with-an-administration-time-of-3-5-minutes#:~:text=The%20subcutaneous%20formulation%20of%20nivolumab,and%20head%20and%20neck%20cancers</a>.

Biotech

General

MHRA Authorizes Cancer Treatment Variation With An Administration Time Of 3–5 Minutes; Approved New Under-The-Skin Injection Version Of Nivolumab (Opdivo)

Comments

Direxion Daily CSI 300 China A Share Bull 2X Shares

Notizie

Ultime notizie per Direxion Daily CSI 300 China A Share Bull 2X Shares (ARCA:CHAU)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO